Peptides researched for sarcopenia and age-related muscle loss
Peptides studied in age-related muscle loss, mitochondrial myopathy and GH-axis decline.
Overview
Sarcopenia — the age-related loss of skeletal-muscle mass and function — is one of the more clinically consequential hallmarks of biological ageing. Prevalence rises sharply from age 65, and the downstream effects on fall risk, metabolic flexibility and overall mortality are well-characterised. The underlying biology is multifactorial: mitochondrial dysfunction in muscle fibres, reduced satellite-cell renewal, declining anabolic signalling, and the broader inflammaging state all contribute.
Peptide research has converged on several of these axes. Mitochondrially-derived peptides (MOTS-c, Humanin) and mitochondrial-membrane stabilisers (SS-31/elamipretide) target the muscle-mitochondrial decline. GH-axis peptides (Sermorelin, the CJC-1295/Ipamorelin combination) target the somatopause and the associated reduction in IGF-1-mediated anabolic signalling. Each axis has its own published evidence base, with different strengths and limitations.
This page surveys the published research relevant to muscle ageing. It is a research-context overview, not a clinical protocol. No compound discussed here is licensed in the UK for sarcopenia treatment, and the only approved pharmacological intervention for confirmed GH deficiency in UK guidelines is recombinant human growth hormone (somatropin), which is not a peptide covered on this site.
The biology being targeted
Skeletal-muscle ageing is driven by three converging processes that the peptide literature touches in different ways. The first is mitochondrial dysfunction: muscle fibres from older adults show reduced oxidative capacity, oxidised cardiolipin in the inner mitochondrial membrane, and lower expression of PGC-1α-driven biogenesis programmes. The Siegel et al. 2013 paper demonstrating restoration of aged-muscle physical performance in mice within eight days of SS-31 administration remains one of the most striking proof-of-mechanism findings in this field.
The second is the GH/IGF-1 axis. Adult GH output declines progressively from age 30, driven primarily by reduced hypothalamic GHRH signalling rather than by pituitary failure. Lower IGF-1 reduces myofibrillar protein synthesis and satellite-cell activation. GHRH-analogue peptides (Sermorelin, CJC-1295) stimulate residual pituitary capacity to restore pulsatile GH output with intact feedback regulation — distinct from recombinant GH supplementation, which produces sustained supraphysiological IGF-1 elevation.
The third is anabolic signalling decline and inflammaging. Chronic low-grade elevation of inflammatory cytokines (IL-6, TNF-α) in older muscle reduces myofibrillar protein synthesis and increases proteolysis. Peptides that modulate inflammatory tone — including MOTS-c through its AMPK-PGC-1α effects and GHK-Cu through its broader anti-inflammatory gene-expression signature — touch this third axis indirectly.
Peptides researched in this protocol
The clearest mitochondrial-derived peptide candidate for muscle-ageing research. AMPK activation, increased GLUT4 translocation, mitochondrial biogenesis through PGC-1α — collectively reproducing much of the exercise-training molecular signature in aged muscle. Reynolds et al. 2021 (Nature Communications) demonstrated restoration of age-impaired physical capacity in aged mice receiving MOTS-c.
Mitochondrial-targeted cardiolipin-binding tetrapeptide; the only compound in this list with a multi-phase clinical-trial dataset (MMPOWER programme in primary mitochondrial myopathy). The Siegel et al. 2013 paper remains the canonical mechanistic-rescue demonstration in aged skeletal muscle. Mixed phase III readouts but the human safety dataset is robust.
GHRH 1-29 analogue stimulating pituitary GH release with intact negative feedback. Preserves diurnal pulsatility — distinct from recombinant GH. Modest body-composition effects in older-adult pilot studies; long-term lifespan implications contested by the broader IGF-1/longevity literature.
The combined GHRH-analogue + selective GHS-R agonist protocol. Supra-additive GH release with preserved feedback; the most-discussed research-context GH-axis protocol in peptide literature. Pilot data shows reductions in visceral adipose and increases in lean mass in older adults.
Stack combinations in the literature
Two combination protocols recur in the published research literature. The first pairs a mitochondrial-axis intervention (SS-31 or MOTS-c) with a GH-axis intervention (CJC-1295/Ipamorelin), on the rationale that mitochondrial restoration and anabolic signalling restoration target orthogonal mechanisms. The mechanistic case is straightforward; direct combination-trial data is absent.
The second is the CJC-1295/Ipamorelin combination itself — the only stack on this list with phase I clinical pharmacodynamic data demonstrating supra-additive GH release. Body-composition pilot data in older adults shows preferential visceral-adipose reduction with modest lean-mass increase.
Recombinant GH is sometimes discussed as a direct alternative to GHRH-analogue protocols. It is not a peptide research compound — it is a licensed medicine in defined indications — and the IGF-1 supraphysiological elevation it produces is mechanistically distinct from the pulsatile feedback-preserved profile produced by GHRH-analogue + GHRP combinations.
Evidence summary
The MMPOWER-3 phase III trial (Karaa et al. 2020, Neurology) is the most-developed clinical dataset in this protocol vertical. Primary efficacy endpoint (6-minute-walk distance) was not met at week 24 in primary mitochondrial myopathy, but patient-reported fatigue scores improved on active SS-31 treatment. Safety profile was favourable across the programme.
Reynolds et al. 2021 (Nature Communications) demonstrated that MOTS-c administration restored age-impaired physical capacity in mice and partially reproduced the molecular signature of exercise training in aged skeletal muscle. The translational implications are significant; human trial data is not yet published.
GHRH-analogue body-composition data in older adults (Sigalos & Pastuszak 2018, Sex Med Rev) shows consistent modest reduction in visceral adipose and increase in lean mass across pilot studies. Long-term lifespan implications are contested — lower IGF-1 is associated with longer life in multiple animal models and in some human cohorts (Laron syndrome). The healthspan case for GHRH-axis restoration in older adults is stronger than the lifespan case.
Safety profile & UK regulatory framing
Across all four compounds the published safety profiles are favourable in available preclinical and (for SS-31) clinical-trial data. The most common adverse events in human use are injection-site reactions and occasional mild transient gastrointestinal upset. No mutagenic or organ-specific toxicity signal has emerged from the available data.
The principal class-effect concern for the GHRH-axis compounds is the IGF-1 axis itself. Lower IGF-1 is associated with longer lifespan in multiple animal models (Ames dwarf, GH-receptor-deficient mice) and in the human Laron-syndrome population. Restoring youthful IGF-1 in older adults using a peptide GH-axis protocol is therefore not unambiguously supported as a longevity intervention. Active malignancy is an absolute contraindication for GHRH-axis intervention.
Under UK law none of the compounds discussed is a licensed sarcopenia treatment. Research-grade material is supplied for laboratory and preclinical work only.
Frequently asked questions
Is sarcopenia a recognised UK medical diagnosis?
Yes. Sarcopenia is recognised as a clinical diagnosis in UK medicine, with diagnostic criteria including reduced grip strength, slow gait speed and reduced appendicular lean-mass index measured by DEXA. UK-licensed pharmacological interventions are limited and the standard approach prioritises resistance-training and nutritional intervention.
Does any peptide outperform resistance training?
No. Resistance training remains the most-evidenced intervention for muscle ageing, with effect sizes substantially exceeding those reported for any peptide intervention in the available literature. Peptide research in this space is positioned as adjunct or as targeted intervention for populations unable to undertake resistance training, not as a replacement.
What is the IGF-1 longevity paradox?
Lower IGF-1 is associated with longer lifespan in multiple animal models and in the human Laron-syndrome population. Yet GH/IGF-1 decline produces measurable changes in body composition and recovery capacity that are typically framed as undesirable. Whether restoring youthful IGF-1 profiles in older adults is net-beneficial for healthspan and lifespan is genuinely unresolved. See our dedicated research summary on the GH-axis paradox.
Is recombinant GH a peptide?
Recombinant human GH (somatropin) is a polypeptide therapeutic — it is the human growth hormone protein produced in mammalian or bacterial expression systems and supplied as a licensed medicine for defined GH-deficiency indications. It is not covered on this site because it is a licensed medicine, not a research peptide.
Can MOTS-c replace exercise?
No. MOTS-c is described as an exercise-mimetic because it reproduces parts of the molecular signature of endurance training in skeletal muscle, but the breadth and magnitude of exercise's effects are not reproduced by MOTS-c administration. The mechanistic interest is in populations unable to exercise — sarcopenia in advanced frailty, mitochondrial myopathy — not as a replacement for training in able populations.